Hydrolases (3. ) (e.g., Urease, Lipase, Asparaginase, Muramidase, Etc.) Patents (Class 424/94.6)
  • Patent number: 10881736
    Abstract: The present disclosure provides biophotonic compositions, kits and their uses. In particular, the biophotonic compositions of the present disclosure are substantially resistant to leaching such that low amounts of chromophores present in the biophotonic composition leach out of the composition. The biophotonic compositions and their uses are useful for promoting repair of non-healing wounds.
    Type: Grant
    Filed: July 2, 2014
    Date of Patent: January 5, 2021
    Assignee: KLOX TECHNOLOGIES INC.
    Inventors: Nikolaos Loupis, Remigio Piergallini, Shipra Rastogi
  • Patent number: 10874719
    Abstract: The present invention provides a method of treating or preventing immunoinflammatory, vascular, thrombotic or ischemic disorders in a subject, the method comprises administering to the subject an agent which dissipates nucleotide phosphates or generates a product which stimulates adenosine receptors. The present invention also provides a method of treating or preventing immunoinflammatory, thrombotic or ischemic disorders in a subject by inhibiting leukocyte infiltration into a site which comprises administering to the subject an effective amount a described agent. Agents described for use in the methods of the invention include CD73, a fragment a mutant, or a modified form thereof.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: December 29, 2020
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: David J. Pinsky, Danica Petrovic-Djergovic
  • Patent number: 10864255
    Abstract: The present invention comprises a method to diminish and/or eliminate atherosclerotic plaques, in mammals, through direct and indirect treatment of these plaques, in situ, using suitable substances which are capable of lipid removal, primarily through hydrolysis, either by a catalytic or stoichiometric process, wherein the substance targets receptors in and/or on the cell which lead to uptake into the lysosome. Such substances used to diminish and/or eliminate atherosclerotic plaques are generally comprised of lipid hydrolyzing proteins and/or polypeptides.
    Type: Grant
    Filed: February 13, 2017
    Date of Patent: December 15, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: Gregory A. Grabowski, Hong Du
  • Patent number: 10858642
    Abstract: The present invention relates to immunogenic polypeptide fragments of a human Arginase protein. The fragments are in particular useful for the treatment or prevention of cancer.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: December 8, 2020
    Assignee: IO Biotech ApS
    Inventor: Mads Hald Andersen
  • Patent number: 10772940
    Abstract: The presently-disclosed subject matter includes isolated polypeptides that comprise a butyrylcholinestrase (BChE) polypeptide and a second polypeptide. The BChE polypeptide as well as the second polypeptide can be variants and/or fragments thereof. The presently-disclosed subject matter also includes a pharmaceutical composition that comprises the present isolated polypeptide and a suitable pharmaceutical carrier. Further still, methods are provided for treating cocaine-induced conditions, and comprise administering the isolated polypeptide and/or pharmaceutical compositions thereof to an individual.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: September 15, 2020
    Assignee: University of Kentucky Research Foundation
    Inventors: Chang-Guo Zhan, Fang Zheng, Hsin-Hsiung Tai, Xiabin Chen, Liu Xue, Shurong Hou
  • Patent number: 10775597
    Abstract: An interferometric scattering microscope is adapted by performing spatial filtering of output light, which comprises both light scattered from a sample location and illuminating light reflected from the sample location, prior to detection of the output light. The spatial filtering passes the reflected illumination light but with a reduction in intensity that is greater within a predetermined numerical aperture than at larger numerical apertures. This enhances the imaging contrast for coherent illumination, particularly for objects that are weak scatterers.
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: September 15, 2020
    Assignee: Oxford University Innovation Limited
    Inventors: Philipp Kukura, Alexander Weigel, Justin Benesch
  • Patent number: 10745664
    Abstract: The present invention is directed to novel methods comprising the isolation of viable fetal progenitor cells from organs of aborted fetus. The invention comprises the use of natural proteolytic, collagenolytic and fibrinolytic activity of autologous abortive placenta tissue extract.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: August 18, 2020
    Assignee: Reelabs Private Limited, a Company Incorporated Under Provisions of The Companies Act 1956
    Inventors: Abhijit Bopardikar, Rohit Kulkarni, Sunil Pophale, Andrii Kukharchuk, Oleksandr Kukharchuk, Padma Priya Anand Baskaran
  • Patent number: 10745677
    Abstract: Provided herein are systems, compositions, and methods of introducing protective and/or loss-of-function variants of CCR5 and CCR2. Variants may be introduced using a CRISPR/Cas9-based nucleobase editor or other guide nucleotide sequence-programmable DNA binding protein domain-based fusion protein described herein. Further provided herein are compositions and methods of preventing and treating conditions related to HIV infection and progression as well as to AIDS.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: August 18, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Juan Pablo Maianti, David R. Liu
  • Patent number: 10655099
    Abstract: The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: May 19, 2020
    Assignees: Baxalta Incorporated, Baxalta GmbH
    Inventors: Leopold Grillberger, Manfred Reiter, Wolfgang Mundt, Friedrich Dorner
  • Patent number: 10640806
    Abstract: Methods and compositions to restore function to acidified T cells are provided. The methods comprise administering urease to the T cells. Compositions comprise urease.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: May 5, 2020
    Assignee: Helix BioPharma Corp.
    Inventors: Wah Yau Wong, Baomin Tian, Kim Gaspar, Marni Diane Uger, Sven Rohmann, Heman Lap Man Chao
  • Patent number: 10626387
    Abstract: The present invention discloses a lysin that is capable of killing Staphylococcus and the use thereof, belonging to the field of biological agents. The present invention discloses the amino acid sequence and the encoding gene sequence of the lysin. This lysin keeps active in a wide range of pH. It has lytic activity against Staphylococcus in pH 4-11. The recombinant protease constructed by the encoding gene can be solubly expressed in E. coli strain BL21 (DE3). The lysin can be used to effectively kill multiple species Staphylococcus in vitro, including methicillin sensitive Staphylococcus aureus (MSSA) and methicillin resistant Staphylococcus aureus (MRSA) isolated in clinics. This lysin can be used as an antibiotic for the treatment of staphylococcal infections in vivo. This lysin is also able to rapidly lyse staphylococcal cell wall; as a result, intracellular substances such as ATP and DNA are released. Those released substances can be used to detect the type of Staphylococcus.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: April 21, 2020
    Assignee: Phagelux, Inc.
    Inventors: Hongping Wei, Hang Yang, Junping Yu
  • Patent number: 10563183
    Abstract: This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme.
    Type: Grant
    Filed: January 12, 2018
    Date of Patent: February 18, 2020
    Assignee: BioMarin Pharmaceutical Inc.
    Inventors: Erno Pungor, Charles Hague, Zhi Chen
  • Patent number: 10526593
    Abstract: The present invention discloses a composition for biomass hydrolysis. The components of the composition may be obtained by biological or synthetic means. Synthetically, the components of the composition of the present invention may be obtained by amino acid synthesis or may be procured commercially.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: January 7, 2020
    Assignees: International Centre For Genetic Engineering & Biotechnology, Department of Biotechnology Ministry of Science & Technology
    Inventors: Syed Shams Yazdani, Funso Emmanuel Ogunmolu
  • Patent number: 10407671
    Abstract: The present invention provides compositions of recombinant human lysosomal acid lipase having particular glycosylation patterns for internalization into target cells, a vector containing the nucleic acid encoding human lysosomal acid lipase, a host cell transformed with the vector, pharmaceutical compositions comprising the recombinant human lysosomal acid lipase and method of treating conditions associated with lysosomal acid lipase deficiency.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: September 10, 2019
    Assignee: Alexion Pharmaceuticals, Inc.
    Inventors: Anthony Quinn, Alex J. Harvey
  • Patent number: 10344270
    Abstract: The present invention provides, among other things, improved methods for purifying I2S protein produced recombinantly for enzyme replacement therapy. The present invention is, in part, based on the surprising discovery that recombinant I2S protein can be purified from unprocessed biological materials, such as, I2S-containing cell culture medium, using a process involving as few as four chromatography columns.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: July 9, 2019
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventor: Dave Nichols
  • Patent number: 10308920
    Abstract: The invention provides hydrolases, polynucleotides encoding them, and methods of making and using these polynucleotides and polypeptides. In one aspect, the invention is directed to polypeptides, e.g., enzymes, having a hydrolase activity, e.g., an esterase, acylase, lipase, phospholipase (e.g., phospholipase A, B, C and D activity, patatin activity, lipid acyl hydrolase (LAH) activity) or protease activity, including thermostable and thermotolerant hydrolase activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The hydrolase activities of the polypeptides and peptides of the invention include esterase activity, lipase activity (hydrolysis of lipids), acidolysis reactions (to replace an esterified fatty acid with a free fatty acid), transesterification reactions (exchange of fatty acids between triglycerides), ester synthesis, ester interchange reactions, phospholipase activity and protease activity (hydrolysis of peptide bonds).
    Type: Grant
    Filed: October 7, 2015
    Date of Patent: June 4, 2019
    Assignee: DSM IP ASSETS B.V.
    Inventors: Uwe T. Bornscheuer, David Weiner, Tim Hitchman, Jonathan Lyon, Sirirung Wongsakul
  • Patent number: 10293032
    Abstract: Viral infections of the eye, and particularly viral infections in the Herpesviridae and Adenoviridae families, can be treated by administration of a pharmaceutical made up of an enzymatically active ribonuclease and a vehicle. Advantageously, the enzymatically active ribonuclease is ranpirnase, the '805 variant, rAmphinase 2, and Amphinase 2, and the vehicle is an aqueous solution.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: May 21, 2019
    Assignee: TAMIR BIOTECHNOLOGY, INC.
    Inventors: Luis Squiquera, Jamie Sulley
  • Patent number: 10286046
    Abstract: The present invention provides a therapeutic agent for disc herniation, which has extremely few adverse side effects, can achieve a prolonged pain-ameliorating effect when administered in only a single dose, and can exhibit a high therapeutic effect and high safety in clinical applications. The present invention relates to a therapeutic agent for disc herniation, which is characterized by containing chondroitinase ABC as an active ingredient and being administered in such a manner that the ingredient can be administered into a human disk in an amount of 1-8 units per disk.
    Type: Grant
    Filed: September 8, 2016
    Date of Patent: May 14, 2019
    Assignee: Seikagaku Corporation
    Inventors: Taiichi Sirogane, Takao Murayama, Masafumi Yaguchi
  • Patent number: 10265355
    Abstract: The present invention relates to a Myoviridae bacteriophage Esc-COP-1 that is isolated from the nature and can kill specifically Shigatoxin-producing type F18 E. coli strains, which has a genome represented by the nucleotide sequence of SEQ. ID. NO: 1 (Accession NO: KCTC 12662BP), and a method for preventing and treating the infections of Shigatoxin-producing type F18 E. coli using the composition comprising said bacteriophage as an active ingredient.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: April 23, 2019
    Assignee: INTRON BIOTECHNOLOGY, INC.
    Inventors: Seong Jun Yoon, Sang Hyeon Kang, Soo Youn Jun, Hyoun Rok Paik, Jee Soo Son, Suk Hwang Park, Byung Kuk Kim
  • Patent number: 10196698
    Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for assessing prostate cancer. In a specific embodiment, present inventors have developed and applied a new technology and associated computation methods enabling simultaneous genome-scale analysis of genetic (copy number) and epigenetic (total methylation (TM) and allele-specific methylation (ASM) alternation, This method, called MBD-SNP, features affinity enrichment or methylated genomic DNA fragments using a methyl-binding domain polypeptide.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: February 5, 2019
    Assignee: The Johns Hopkins University
    Inventors: Srinivasan Yegnasubramanian, G. Steven Bova, Martin Aryee, William B. Isaacs, William G. Nelson
  • Patent number: 10188705
    Abstract: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
    Type: Grant
    Filed: April 12, 2017
    Date of Patent: January 29, 2019
    Assignees: Icahn School of Medicine at Mount Sinai, Genzyme Corporation
    Inventors: Edward H. Schuchman, Robert J. Desnick, Gerald F. Cox, Laura P. Andrews, James M. Murray
  • Patent number: 10160960
    Abstract: Provided are mutant cocaine esterase polypeptides and PEGylated formulations thereof.
    Type: Grant
    Filed: August 6, 2014
    Date of Patent: December 25, 2018
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: Donald Landry, Chang-Guo Zhan
  • Patent number: 10106854
    Abstract: The present application concerns methods and tools for diagnosing prostate cancer and furthermore concerns methods and tools for prognosing disease progression of prostate cancer. The method comprises determining methylation level of the genes C1orf114, HAPLN3, AOX1, GAS6, ST6GALNAC3 and ZNF660 and comparing the result with a control, thus obtaining a response which is used for diagnosing a prostate cancer and/or for prognosing aspects of an individual suffering from prostate cancer.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: October 23, 2018
    Assignees: Aarhus Universitet, Region Midtjylland
    Inventors: Torben Falck Ørntoft, Karina Dalsgaard Sørensen, Christa Haldrup
  • Patent number: 10093909
    Abstract: Polypeptides having phytase activity and polynucleotide sequences encoding the phytases are provided. The gene expresses the phytase at a level of at least 7 g/l to 40 g/L. The phytases have higher specific activity, retain activity at low pH, retain activity at high temperature, increased phosphorous equivalency, increased phosphorous bioavailability, and increased phosphorous hydrolysis. The phytases can be used in a variety of industries including food, feed, ethanol production, pharmaceuticals, and cleaning.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: October 9, 2018
    Assignee: BASF ENZYMES LLC
    Inventor: Arne I. Solbak, Jr.
  • Patent number: 10081800
    Abstract: Novel lactonases are provided.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: September 25, 2018
    Assignee: Fornia BioSolutions, Inc.
    Inventors: Goutami Banerjee, Jie Yang, Khin Oo, Xiyun Zhang, Eric Lin Hu, Tatsuya Fukushima
  • Patent number: 10058596
    Abstract: Methods and compositions for the enzymatic debridement of wounds are provided. Methods for preparing enzymatic debridement compositions are also provided. In one embodiment, an enzymatic debridement composition prepared by dissolving crude bromelain in a composition comprising a weak acid, and filtering and/or dialyzing the dissolved crude bromelain to obtain the enzymatic debridement composition is provided.
    Type: Grant
    Filed: December 18, 2012
    Date of Patent: August 28, 2018
    Assignee: KCI Licensing, Inc.
    Inventor: Douglas Philip Hanson
  • Patent number: 10016559
    Abstract: Embodiments relate to systems, methods and devices for delivering a drug or other therapy to a patient with an ambulatory infusion pump configured to provide a series of tolerance-building steps leading up to a plateau delivery rate. The plateau delivery rate is maintained until the prescribed amount of drug or therapy fluid is delivered to the patient. Embodiments of the invention include providing the patient or other user with a mechanism to decrease, or step down, the therapy delivery rate if a tolerance was not achieved at a lower rate, and providing notifications prior to a step up in a dosage delivery rate.
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: July 10, 2018
    Assignee: Smiths Medical ASD, Inc.
    Inventors: David DeBelser, Clinton Robert Hetchler, David Pardee Sours, Michael Wade Kersch
  • Patent number: 9976187
    Abstract: Different combinations of methylation status based biomarkers can be used to test for prostate cancer with high sensitivity and high specificity.
    Type: Grant
    Filed: June 11, 2013
    Date of Patent: May 22, 2018
    Assignee: KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Vladimir Bajic, Hicham Mansour, Roberto Incitti
  • Patent number: 9949925
    Abstract: Disclosed herein are bactericidal compositions that are effective against pathogenic biofilms, especially against biofilms formed by Pseudomonas aeruginosa. The disclosed compositions comprise escapin intermediate products which can reduce the biofilm viability and biofilm matrix of P. aeruginosa.
    Type: Grant
    Filed: April 1, 2016
    Date of Patent: April 24, 2018
    Assignee: GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION
    Inventors: Charles D. Derby, Phang C. Tai, Eric S. Gilbert
  • Patent number: 9931437
    Abstract: The invention provides a scaffold of extracellular matrix polymers with recombinant chimeric peptides tethered thereto. The invention also provides recombinant chimeric peptides of antimicrobial peptides and extracellular matrix binding domains. The invention also provides methods for treating chronic wounds using the scaffold and/or recombinant chimeric peptides.
    Type: Grant
    Filed: February 4, 2015
    Date of Patent: April 3, 2018
    Assignee: WORCESTER POLYTECHNIC INSTITUTE
    Inventors: Marsha Rolle, Fioleda Prifti, Christopher Malcuit, Terri Anne Camesano, Tanja Dominko, Denis Kole
  • Patent number: 9914916
    Abstract: The present invention provides isolated dimeric Streptococcus-specific phage lysins having two Streptococcus-specific phage lysin monomers covalently linked to each other, and having killing activity against one or more Streptococcus bacteria. Also provided for are pharmaceutical compositions of dimeric lysins and their use in therapeutic treatment or alleviation of infections or bacterial colonizations. The dimeric lysins may also be used to decontaminate porous and non-porous surfaces or devices.
    Type: Grant
    Filed: January 27, 2016
    Date of Patent: March 13, 2018
    Assignee: THE ROCKEFELLER UNIVERSITY
    Inventors: Vincent A. Fischetti, Gregory Resch
  • Patent number: 9896672
    Abstract: A composition comprising recombinant iduronate-2-sulfatase (IDS) and a method for producing a purified recombinant IDS are provided. The glycosylation pattern and formylglycine content of the IDS composition are different from those of ELAPRASE® and have superior pharmaceutical efficacy and are safer than the conventional agent and thus can be effectively used for the therapy of Hunter syndrome.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: February 20, 2018
    Assignees: GREEN CROSS CORPORATION, MediGeneBio Corporation
    Inventors: Thong-Gyu Jin, Yo Kyung Chung, Sang Hoon Paik, Yoo Chang Park, Jinwook Seo, Yong Woon Choi, Jong Mun Son, Yong-Chul Kim
  • Patent number: 9889203
    Abstract: Disclosed herein are methods of chemical conjugation comprising contacting a lysosomal enzyme with a first crosslinking agent to introduce aldehyde groups; contacting a lysosomal targeting peptide with a second crosslinking agent to introduce a hydrazide group at the N-terminal residue; contacting the lysosomal enzyme with aldehyde groups of step a. with the lysosomal targeting peptide with a hydrazide group at the N-terminal residue of step b; and forming a lysosomal enzyme-lysosomal targeting peptide conjugate.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 13, 2018
    Assignee: AMICUS THERAPEUTICS, INC.
    Inventor: Hung Do
  • Patent number: 9867875
    Abstract: Methods and compositions comprising recombinant Arginase I proteins which are capable of depleting the plasma arginine levels in a subject are disclosed. The methods and compositions can be used to modulate the activity of the immune system in a subject. Modulation of the immune system is useful in the treatment of immune disorders and in preventing rejection of a transplanted organ, tissue, or cell. The methods and compositions can also be used to treat a bone condition of a subject.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: January 16, 2018
    Assignee: BIO-CANCER TREATMENT INTERNATIONAL LIMITED
    Inventors: Gernot Schabbauer, Stephen Bluml, Emine Sahin-Heco, Paul Cheng, Li Chen
  • Patent number: 9844585
    Abstract: An embodiment of the invention is directed to a microfabricated, silicon-based, Convection Enhanced Delivery (CED) device. The device comprises a silicon shank portion, at least one individual parylene channel disposed along at least a part of an entire length of the shank, wherein the channel has one or more dimensioned fluid exit ports disposed at one or more respective locations of the channel and a fluid (drug) input opening. The fluid input opening may be configured or adapted to be connected to a fluid reservoir and/or a pump and/or a meter and/or a valve or other suitable control device(s) or apparatus that supplies and/or delivers fluid (e.g., a drug) to the microfabricated device. The device may have multiple channels disposed side by side or in different surfaces of the device. The device may be rigid, or flexible, in which case a flexible device can be attached to a bio-degradable support scaffold that provides sufficient structural rigidity for insertion of the device into the target tissue.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: December 19, 2017
    Assignees: YALE UNIVERSITY, CORNELL UNIVERSITY
    Inventors: William L. Olbricht, Keith B. Neeves, Conor Foley, Russell T. Matthews, W. Mark Saltzman, Andrew Sawyer
  • Patent number: 9839679
    Abstract: A method for modifying access of cells to extravascular spaces and regions comprising administering to a patient an enzyme that cleaves chondroitin sulfate proteoglycans is provided. It has been found that administration of an enzyme that cleaves chondroitin sulfate proteoglycans to a patient disrupts extravasation of cells from the blood stream into tissue. The present invention provides methods of reducing penetration of cells associated with inflammation into tissue of a patient. Several methods are also provided for the regulation and suppression of inflammation comprising administering enzymes that digest chondroitin sulfates. Also provided are methods of treating and preventing inflammation associated with infection, injury and disease.
    Type: Grant
    Filed: February 26, 2014
    Date of Patent: December 12, 2017
    Assignee: Acorda Therapeutics, Inc.
    Inventors: Elliott A. Gruskin, Jack L. Tseng, Anthony O. Caggiano
  • Patent number: 9839676
    Abstract: The invention provides a method for treating cancer in a subject or a method of inducing an anti-tumour effect including reducing tumour volume, inhibiting or slowing tumour growth, inhibiting tumour progression, altering the metabolic activity of a tumour, inducing quiescence of a tumour, inhibiting or reducing metastasis, inhibiting or reducing tumour invasiveness, reducing tumour weight, reducing tumour neovascularisation, improving time to disease progression (TDP) and/or improving survival, the method comprising administering to the subject an effective amount of angiogenin or an angiogenin agonist.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: December 12, 2017
    Assignees: Murray Goulburn Co-Operative Co., Limited, AGRICULTURE VICTORIA SERVICES PTY LTD
    Inventors: Peter Hobman, Andrew Brown
  • Patent number: 9827264
    Abstract: A method and system for identifying and treating various medical conditions caused by toxins, pathogens, hormonal imbalances and other factors involving intravenous therapy.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: November 28, 2017
    Inventor: Wyatt J. Palumbo
  • Patent number: 9816006
    Abstract: A coating process includes the successive steps of preparing the zone to be treated. At least one coat of a primer is applied to the prepared zone to obtain a thickness ranging from 100 to 450 micrometers. The zone to be treated is then reconditioned and a least one top coat is applied to obtain a thickness ranging from 100 to 450 micrometers.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: November 14, 2017
    Assignee: SARL SIMON
    Inventor: Dominique Simon
  • Patent number: 9814664
    Abstract: A composition for treating keratin surfaces to stimulate selective catabolysis and improve cellular viability comprising at least one autophagy activator and at least one DNA repair enzyme, and a method for improving selective catabolysis and cellular viability by treating with the composition.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: November 14, 2017
    Assignee: ELC Management LLC
    Inventors: Nadine A. Pernodet, Donald F. Collins, Dawn Layman, Daniel B. Yarosh
  • Patent number: 9765313
    Abstract: The present invention relates to the field of genetic engineering, in particular, the present invention relates to a method for producing a phytase variant with an improved thermal stability, and a phytase variant and the use thereof. The phytase variant contains at least one proline modification, compared to the phytase from Escherichia coli and other mutants thereof. The phytase variants with the modification have preferably improved properties, such as the thermal stability, optimal reaction temperature, pH property, specific activity, protease resistance and performance in animal feeds.
    Type: Grant
    Filed: November 12, 2013
    Date of Patent: September 19, 2017
    Assignee: Feed Research Institute, Chinese Academy of Agricultural Sciences
    Inventors: Bin Yao, Huoqing Huang, Huiying Luo, Chao Shao, Yingguo Bai, Yaru Wang, Peilong Yang, Pengjun Shi, Kun Meng, Heng Zhao, Rui Ma
  • Patent number: 9752197
    Abstract: The present invention relates to a method for detecting methylation of the bowel-cancer-specific methylation marker GPM6A (NM_201591, glycoprotein M6A) gene in order to diagnose bowel cancer, and more specifically relates to a method for providing information for diagnosing bowel cancer by detecting the methylation of a bowel-cancer-specific marker gene that is specifically methylated in bowel cancer cells. The method for detecting methylation and a diagnostic composition, kit and nucleic-acid chip according to the present invention can be used to advantage in diagnosing bowel cancer more accurately and quickly than by normal methods as they permit bowel cancer to be diagnosed at the initial genetic transformation step and so allow early diagnosis.
    Type: Grant
    Filed: January 29, 2016
    Date of Patent: September 5, 2017
    Assignee: GENOMICTREE, INC.
    Inventors: Sung Whan An, Tae Jeong Oh
  • Patent number: 9719074
    Abstract: The present invention provides, among other things, methods and compositions for production of recombinant I2S protein with improved potency and activity using cells co-express I2S and FGE protein. In some embodiments, cells according to the present invention are engineered to simultaneously over-express recombinant I2S and FGE proteins. Cells according to the invention are adaptable to various cell culture conditions. In some embodiments, cells of the present invention adaptable to a large-scale suspension serum-free culture.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: August 1, 2017
    Assignee: Shire Human Genetic Therapies, Inc.
    Inventors: Ferenc Boldog, Michael Heartlein
  • Patent number: 9714427
    Abstract: The present invention provides methods and compositions for inducing expression of Ube3a in a cell by contacting the cell with a topoisomerase inhibitor. Particular embodiments include a method of treating a genomic imprinting disorder, such as Angelman syndrome, in a subject by administering to the subject an effective amount of a topoisomerase inhibitor.
    Type: Grant
    Filed: November 9, 2011
    Date of Patent: July 25, 2017
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Benjamin David Philpot, Mark John Zylka, Bryan Leo Roth, John Arthur Allen, Hsien-Sung Huang
  • Patent number: 9687534
    Abstract: A therapeutic agent for the treatment of the symptoms of addiction and the method for preparing the therapeutic agent is disclosed. The therapeutic agent is a stable pharmaceutical preparation containing, but not limited to, digestive/pancreatic enzymes. The therapeutic agent may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic agent may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using of a biomarker, the presence of chymotrypsin in the gastrointestinal tract to determine the presence of symptoms of addiction, and the likelihood of relapsing into addiction is disclosed.
    Type: Grant
    Filed: March 5, 2015
    Date of Patent: June 27, 2017
    Assignee: Curemark, LLC
    Inventor: Joan M. Fallon
  • Patent number: 9663775
    Abstract: The present invention relates to isolated polypeptides having lysozyme activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Grant
    Filed: November 23, 2012
    Date of Patent: May 30, 2017
    Assignee: Novozymes A/S
    Inventor: Kirk Matthew Schnorr
  • Patent number: 9655954
    Abstract: The invention relates to dose escalation enzyme replacement therapy using acid sphingomyelinase (ASM) for the treatment of human subjects having acid sphingomyelinase deficiency (ASMD), and, in particular, patients with non-neurological manifestations of Niemann-Pick Disease (NPD), and in certain embodiments, NPD type B.
    Type: Grant
    Filed: July 8, 2015
    Date of Patent: May 23, 2017
    Assignees: Icahn School of Medicine at Mount Sinai, Genzyme Corporation
    Inventors: Edward H. Schuchman, Robert J. Desnick, Gerald F. Cox, Laura P. Andrews, James M. Murray
  • Patent number: 9651558
    Abstract: The invention relates to bacterial cell surface display of post-translationally modified heterologous proteins. Provided is an isolated nucleic acid construct encoding a proteinaceous substance comprising, from the N-terminus to the C-terminus, at least (a) an N-terminal a lantibiotic leader sequence; (b) an amino acid sequence of interest to be post-translationally modified to a dehydroresidue- or thioether-bridge containing polypeptide; (c) a hydrophilic cell-wall spanning domain; (d) a sortase recognition motif; (e) a hydrophobic membrane spanning domain and (f) a C-terminal charged membrane anchoring domain. Also provided is a Gram-positive host cell expressing the construct, as well as a library of host cells.
    Type: Grant
    Filed: July 6, 2011
    Date of Patent: May 16, 2017
    Assignee: LanthioPep B.V.
    Inventor: Tjibbe Bosma
  • Patent number: 9631186
    Abstract: Disclosed herein are methods and compositions for generating a single-stranded break in a target sequence, which facilitates targeted integration of one or more exogenous sequences.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: April 25, 2017
    Assignee: Sangamo BioSciences, Inc.
    Inventor: Jianbin Wang
  • Patent number: RE47233
    Abstract: The present invention provides a pharmaceutical composition containing albumin-binding arginine deiminase fusion protein (AAD) for treating cancer or other arginine-dependent diseases. The AAD fission protein can be purified from both soluble and insoluble fractions of crude proteins, it binds to human serum albumin (HSA) and has its high activity with longer half life for efficient depletion of arginine in cancer cells. The specific activities of wild-type ADI and AAD in the present invention are 8.4 and 9.2 U/mg (at physiological pH 7.4), respectively. The AAD used in the present invention can be used in the treatment of various cancers (e.g. pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer & brain cancer) and curing arginine-dependent diseases.
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: February 12, 2019
    Assignee: Vision Global Holdings Ltd.
    Inventors: Bing Lou Wong, Norman Fung Man Wai, Sui Yi Kwok, Yun Chung Leung